Etoposide - SuperGen

Drug Profile

Etoposide - SuperGen

Alternative Names: EtopoExtra

Latest Information Update: 22 Mar 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SuperGen
  • Class Antineoplastics; Tetrahydronaphthalenes
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Small cell lung cancer; Testicular cancer

Most Recent Events

  • 30 Jul 2001 This compound is still in active development
  • 08 May 1998 Preclinical development for Small cell lung cancer in USA (Parenteral)
  • 08 May 1998 Preclinical development for Testicular cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top